MSB - MESABI TRUST ()

MSBのニュース

   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd By Investing.com  2021/02/11 13:03:02 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd
   Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study  2021/02/11 05:41:00 Benzinga
Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the …
   AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre half year results  2021/02/11 04:46:40 The Australian Financial Review
On a big day of the interim profit reporting season, we have results from AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre. Find full reports and analysis here.
   Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others  2021/02/09 18:30:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cell therapy market accounted for…
   Maxim Group Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/09 09:10:06 Investing.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd
   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd By Investing.com  2021/02/11 13:03:02 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd
   Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study  2021/02/11 05:41:00 Benzinga
Positive results from Mesoblast Limited’s (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the …
   AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre half year results  2021/02/11 04:46:40 The Australian Financial Review
On a big day of the interim profit reporting season, we have results from AMP, Telstra, Transurban, Westfield, GrainCorp, ASX, Magellan, Downer EDI, Mesoblast and Ecofibre. Find full reports and analysis here.
   Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others  2021/02/09 18:30:00 PR Newswire
DUBLIN, Feb. 9, 2021 /PRNewswire/ -- The "Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global cell therapy market accounted for…
   Maxim Group Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/09 09:10:06 Investing.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd
   Dawson James Stick to Their Buy Rating for Mesoblast Ltd By Investing.com  2021/02/02 09:14:14 Investing.com
Dawson James Stick to Their Buy Rating for Mesoblast Ltd
   ASX climbs; Felix jumps on ASX debut  2021/01/11 20:37:41 The Australian Financial Review
Australian shares are trading higher, supported by gains for the major banks, ARB, Super Retail and Mesoblast. Software provider Felix jumps on its first day as listed ASX company but PolyNovo and Altium are under pressure. Miners are also lagging the market.
   Mesoblast (ASX:MSB) trial results boost shares : ASX closed 0.9% lower  2021/01/11 06:00:40 Bourse Data
11 Jan 2021 - The Australian sharemarket slid today closing 61 points down, or 0.9 per cent lower at 6,697. Shares in Resmed (ASX:RMD) did well today. Shares in Westgold Resources (ASX:WGX) dropped along with Perseus Mining (ASX:PRU). Mesoblast (ASX:MSB) reports that their rexlemestrocel-L drug has shown to be effective in a Phase 3 trial.
   Mesoblast tipped to need $US75m cash injection  2021/01/07 05:26:24 The Australian Financial Review
A leading healthcare analyst has warned Mesoblast faces cashflow problems in 2021 with no near-term significant revenue opportunity.
   Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd  2020/12/18 13:15:37 Investing.com
Chardan Capital Stick to Their Sell Rating for Mesoblast Ltd

calendar